Eterna Therapeutics (ERNA) - 2021 Q2 - Quarterly Report
Eterna Therapeutics (ERNA)2021-08-13 21:16UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________ Commission file number: 001-11460 Brooklyn ImmunoTherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware ...